<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218036</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09262-8</org_study_id>
    <secondary_id>P50DA009262-08</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218036</nct_id>
  </id_info>
  <brief_title>Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8</brief_title>
  <official_title>Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine two medications, modafinil and citalopram, in the
      treatment of cocaine dependent individuals who are maintained on methadone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24-week, randomized, double-blind, placebo-controlled study examining two doses of
      modafinil (200 and 400 mg) and citalopram (20 and 40 mg) in the treatment of methadone
      maintained cocaine dependent individuals.

      Participants will first be given methadone to determine its tolerated and effective doses.
      Most participants will be able to reach a stable dose of methadone within 7 to 10 days of
      methadone initiation. When 80% of the projected dose of methadone has been achieved,
      participants will begin the medication regimen of modafinil or citalopram. Modafinil will be
      given over a 7-day period. Dosing of modafinil will begin at 200 mg and, depending on the
      individual, may increase to 400 mg. Citalopram will be given in increasing doses, starting at
      20 mg and increasing to 40mg.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution, end of funding, clinic relocation, recruitment issues
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Abstinence From Cocaine</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Compliance</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Cocaine Abuse</condition>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 200mg / Methadone Maintenance (1.2mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citalopram 20/ Methadone Maintenance 1.2mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citalopram 40/ Methadone Maintenance 1.2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 200mg</intervention_name>
    <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 400mg</intervention_name>
    <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram 20mg</intervention_name>
    <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram 40mg</intervention_name>
    <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets cocaine abuse and dependence criteria (as determined by the SCID)

          -  Meets opiate dependence criteria (as determined by the SCID)

          -  In good general physical and psychiatric health (except for possible acute drug use
             related problems)

        Exclusion Criteria:

          -  Meets diagnostic criteria for other psychiatric disorders, including other forms of
             drug dependence (other than nicotine)

          -  Current cardiovascular disease (as determined by an electrocardiogram)

          -  Circumstances will not allow for completion of study (on probation or parole)

          -  Ethical constraints of supervision do not allow confidentiality (on probation or
             parole)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy M Schmitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Gerard Moeller, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>October 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2018</results_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joy Schmitz</investigator_full_name>
    <investigator_title>Professor - Psy, Behavioral Science</investigator_title>
  </responsible_party>
  <keyword>Cocaine Abuse</keyword>
  <keyword>Opiate Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>54 were enrolled, but only 51 were randomized and started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Modafinil 200mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="P2">
          <title>Modafinil 400mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="P3">
          <title>Citalopram 20mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="P4">
          <title>Citalopram 40mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Methadone Maintenance (1.2mg/kg)</title>
          <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modafinil 200mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Modafinil 400mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Citalopram 20mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="B4">
          <title>Citalopram 40mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="B5">
          <title>Placebo/Methadone Maintenance (1.2mg/kg)</title>
          <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.364" spread="11.474"/>
                    <measurement group_id="B2" value="40.333" spread="8.335"/>
                    <measurement group_id="B3" value="38.769" spread="7.350"/>
                    <measurement group_id="B4" value="36.500" spread="9.050"/>
                    <measurement group_id="B5" value="36.556" spread="7.618"/>
                    <measurement group_id="B6" value="37.510" spread="8.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Abstinence From Cocaine</title>
        <time_frame>12 weeks of treatment</time_frame>
        <population>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil 200mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Modafinil 400mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Citalopram 20mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Citalopram 40mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Methadone Maintenance (1.2mg/kg)</title>
            <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Abstinence From Cocaine</title>
          <population>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention</title>
        <time_frame>12 weeks of treatment</time_frame>
        <population>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil 200mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Modafinil 400mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Citalopram 20mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Citalopram 40mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Methadone Maintenance (1.2mg/kg)</title>
            <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Retention</title>
          <population>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Compliance</title>
        <time_frame>12 weeks of treatment</time_frame>
        <population>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil 200mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Modafinil 400mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Citalopram 20mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Citalopram 40mg/Methadone Maintenance (1.2mg/kg)</title>
            <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Methadone Maintenance (1.2mg/kg)</title>
            <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Compliance</title>
          <population>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The trial was terminated when the PI of the study left the institution. Collected data was stored in a database management system that has since become obsolete and is no longer accessible by current database programs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Modafinil 200mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Modafinil 400mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="E3">
          <title>Citalopram 20mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="E4">
          <title>Citalopram 40mg/Methadone Maintenance (1.2mg/kg)</title>
          <description>10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.</description>
        </group>
        <group group_id="E5">
          <title>Placebo/Methadone Maintenance (1.2mg/kg)</title>
          <description>Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Difficulty recruiting and lower than desired sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joy M Schmitz, PhD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 486-2867</phone>
      <email>Joy.M.Schmitz@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

